Remitting in Medical Technology
Navigation Links
Remitting in Medical Technology
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
... of Neurology, Cologne City Hospitals, Germany. As previously reported, ATL/TV1102 significantly reduced disease activity in patients with Relapsing remitting Multiple Sclerosis (RRMS) in a randomized, double-blind, placebo-controlled Phase II study designed to obtain evidence of ATL/TV1102's effectiveness i...Genmab Announces Upcoming Ofatumumab Studies
... developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country. ......ishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009. "This patent represents an important component in the development of our intellectual property in peptide...
Genmab Reaches Milestone in Ofatumumab Collaboration
...mately USD 6 million) was triggered by treatment of the first patient participating in the Phase II study of ofatumumab for the treatment of relapsing remitting multiple sclerosis (RRMS). "Our collaboration with GSK continues to progress as both companies work towards providing new treatment options for pati...Isis Pharmaceuticals Conference Call Notice
... to view the release titled: Teva Pharmaceuticals & Antisense Therapeutics Announce That ATL/TV 1102, a Novel Drug for the Treatment of Relapsing remitting Multiple Sclerosis Demonstrated Significant Reduction in Disease Activity To access this call via telephone Please call 1-877-548-7901 in the Un......ioavailability and pharmacodynamic effects with PI-2301, provide further evidence that PI-2301 may replace Copaxone as first-line therapy in relapsing remitting multiple sclerosis," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefit of a pro...
Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
...tium of centers involved in studying new therapies for the treatment for multiple sclerosis. This study will enroll patients with aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). Mitoxantrone, a related compound which is less active in preclinical studies, has been app......cumulation of disability in early active relapsing remitting multiple sclerosis (RRMS) patients compared to Reb...ypically characterized by an initial relapsing and remitting phase where episodes of transient neurological com...itive and visual impairments. At onset, relapsing- remitting MS is the most common form of this disease. Abou...
..., Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution, evaluated whether effects on ...
..., Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution, evaluated whether effects on ...
...ial of the investigational T-cell vaccine, Tovaxin(TM), for multiple sclerosis (MS). In this one-year, 8-subject extension clinical trial of relapsing remitting (RRMS) and secondary progressive (SPMS) subjects, Tovaxin therapy was shown to be safe and effective. The "per-protocol" analysis of Tovaxin therapy a...
Other TagsSRSHCHHMEHMEOther Contentsanatomyanatomyanatomyanatomyanatomyanatomyanatomyanatomyanaerobicanaerobicanaerobicanaerobicanaerobicanaerobicanaerobicanaphaseanticodonanticodonantigenantigenantigenantigenantigenantigenantigenantigenantigenvanvanvanvanvanvanshiftshiftshiftshiftshiftshiftshiftshiftshift
SRSSoftclixMulticlixTracheotomyTracheotomiesSpirogardHydrogardOxygardExhalationtintedOmniflexHCH5708HEPAHME
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Fish with attitude: Some like it hot 2WellGen Recognized as Nutraceutical 26amp 3B 238220 3BInnovator 26amp 3B 238221 3B by Global Business Insights 14888 1WellGen Recognized as Nutraceutical 26amp 3B 238220 3BInnovator 26amp 3B 238221 3B by Global Business Insights 14888 2WellGen Recognized as Nutraceutical 26amp 3B 238220 3BInnovator 26amp 3B 238221 3B by Global Business Insights 14888 3Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 1Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 2Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 3Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 4AMA Optics Announces New Brightness Acuity Meter Documents Disabling Glare from Cataract 61591 1AMA Optics Announces New Brightness Acuity Meter Documents Disabling Glare from Cataract 61591 2(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
(Date:12/4/2009)Research and surveillance urged for at-risk patient groups , , FRIDAY, Dec. 4 (HealthDay News) -- Some childhood cancers, particularly Ewing sarcomas and central nervous system tumors, carry t
(Date:12/4/2009)SEATTLE Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins
Breaking Medicine News(10 mins):Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD 2[0] Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor [0] Teens Lose More Weight Using Healthy Strategies[0] Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care[0] Certain Childhood Cancers More Likely to Recur[0] Cholesterol-lowering drugs also may protect stem cell transplant patients from GVHD
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |